Health Condition 1: null- Metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive nonsmall cell lung cancer (NSCLC) Health Condition 2: C341- Malignant neoplasm of upper lobe,bronchus or lung
Conditions
Interventions
None listed
Sponsors
AstraZeneca Pharma India Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1 Patient of either sex and >=18 years of age 2 Patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an appropriate test, who have progressed on or after EGFR TKI therapy by an independent clinical judgment of treating physician based on locally approved prescribing information 3 Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study. Patients must be willing and able to adhere to the prohibitions and restrictions specified in this protocol, as referenced in the informed consent form (ICF).
Exclusion criteria
Exclusion criteria: Patient with either the history of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug. 2 Pregnant and/or lactating women 3 Patients participating in any current or future interventional trial will not be enrolled in the current study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number frequency and proportion of patients with adverse events (AEs) serious adverse events (SAEs) and AEs of special interest (AESI) including interstitial lung disease or pneumonitis like events and on study deathsTimepoint: NA | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactAmit Kumar
AstraZeneca Pharma India Ltd
Outcome results
None listed